logo
Heart disease risk raised by common household products, study finds

Heart disease risk raised by common household products, study finds

Fox News02-05-2025
Chemicals found in plastics have been linked to a multitude of health risks — and now heart disease mortality has been added to the list.
In an analysis of population surveys, researchers at NYU Langone Health discovered that daily exposure to chemicals in common household items could have been a factor in more than 356,000 heart disease deaths in 2018 alone.
That number equates to more than 13% of heart disease-related deaths worldwide for people between 55 and 64 years of age.
The study, which was published in the journal Lancet eBioMedicine on April 29, explored the risks of chemicals called phthalates, which are found in cosmetics, detergents, solvents, plastic pipes, bug repellents and other products, according to an NYU press release.
In this research, the focus was a specific type of phthalate called di-2-ethylhexyl phthalate (DEHP), which is used to make softer, more flexible plastics like food containers and medical equipment, the release stated.
DEHP has been linked to inflammation in the arteries of the heart, making people more susceptible to heart attack or stroke.
To determine levels of DEHP exposure, the researchers analyzed dozens of population surveys spanning 200 countries and territories.
Mortality data was obtained from the Institute for Health Metrics and Evaluation, a research group in the U.S. that collects medical information worldwide to identify trends in public health.
"Our results underscore the urgent need for global regulations to reduce exposure to these toxins."
"By highlighting the connection between phthalates and a leading cause of death across the world, our findings add to the vast body of evidence that these chemicals present a tremendous danger to human health," said study lead author Sara Hyman, BS, an associate research scientist at NYU Grossman School of Medicine, in the release.
The regions with the highest heart disease death tolls linked to phthalates include the Middle East, South Asia, East Asia and the Pacific.
"Our results underscore the urgent need for global regulations to reduce exposure to these toxins, especially in areas most affected by rapid industrialization and plastic consumption," said senior study author Dr. Trasande, the Jim G. Hendrick, MD, professor of pediatrics at NYU Grossman School of Medicine, in the release.
Inflammation is a known cause of coronary artery disease, according to Dr. Jasdeep Dalawari, an Illinois-based interventional cardiologist and regional chief medical officer at VitalSolution, an Ingenovis Health company.
"Our bodies release chemicals and hormones that give directions to the artery to open, close or change diameter," Dalawari, who was not involved in the study, told Fox News Digital.
"This study suggests that microplastics may interfere with those internal signals, so the artery doesn't perform the way it should."
"Microplastics are widely present in a variety of products we use every day, and it's crucial to understand their long-term effects on human health," he added.
Renato Apolito, M.D., medical director of cardiac catheterization at Hackensack Meridian Jersey Shore University Medical Center, agreed that manmade plastic products have long been known and suspected to be health risks.
"These often use highly engineered chemicals where the goal is not quality and safety, but instead cost-effectiveness and convenience," Apolito, who was not involved in the study, told Fox News Digital.
The doctor shared that he stopped using non-stick pans long ago, and mostly uses glass storage and avoids eating and drinking from plastic containers.
Apolito noted, however, that the "longitudinal and observational" nature of the study comes with limitations.
"It is generally used to see if there's any correlation between exposure and health risk, which is then used to study the topic further in a more controlled fashion," Apolito, who was not involved in the study, told Fox News Digital.
"It cannot control for unidentified variations in lifestyles among the people followed."
Senior author Trasande also pointed out the potential limitations.
The analysis does not establish that DEHP caused heart disease and that higher death risks did not take into account other types of phthalates, he stated.
The study also did not include death rates in other age groups, the doctor pointed out, which means the overall death toll is "likely much higher."
Looking ahead, the researchers plan to investigate how reducing phthalate exposure affects mortality rates.
They will also measure the chemical's potential role in other health concerns.
"These studies are typically what are used to study the next step of elucidating cause and effect," Apolito said. "This can lead to the FDA and other policymakers banning or outlawing the use of such products."
"Microplastics are widely present in a variety of products we use every day, and it's crucial to understand their long-term effects on human health."
The study was funded by the National Institutes of Health.
Dalawari suggested that the researchers may want to look at other contributing factors, including air pollution, which has proven to be a "novel non-traditional risk factor" for coronary disease.
"The intersection of pollution, regulation and genetic predisposition provides a complex landscape, and further research is necessary to unravel these connections, paving the way for more informed public health policies and preventive measures," he added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Do Wall Street Analysts Like Solventum Stock?
Do Wall Street Analysts Like Solventum Stock?

Yahoo

timean hour ago

  • Yahoo

Do Wall Street Analysts Like Solventum Stock?

With a market cap of $12.4 billion, Solventum Corporation (SOLV) is an independent healthcare company that develops, manufactures, and markets innovative solutions to meet critical patient and customer needs worldwide. Its business spans four segments: Medsurg; Dental Solutions; Health Information Systems; and Purification and Filtration, serving healthcare providers through direct sales, distribution, and digital platforms. Shares of the Maplewood, Minnesota-based company have outperformed the broader market over the past 52 weeks. SOLV stock has increased 21.4% over this time frame, while the broader S&P 500 Index ($SPX) has gained 16.4%. However, shares of the company have risen 8.1% on a YTD basis, lagging behind SPX's 9.7% return. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Powell, Trump Talks and Other Can't Miss Items this Week Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Looking closer, Solventum stock has also outpaced the Health Care Select Sector SPDR Fund's (XLV) 10.8% decrease over the past 52 weeks. Shares of Solventum rose 2% on Aug. 7 after the company reported Q2 2025 adjusted EPS of $1.69 and revenue of $2.2 billion, above Wall Street forecasts. Growth was driven largely by its MedSurg segment, where sales rose 4.8% to $1.2 billion, reflecting robust demand for wound care and surgical sterilization products, alongside lower expenses. Additionally, management raised its full-year adjusted EPS guidance to $5.80 - $5.95, as easing U.S.-China tariff risks reduced expected headwinds. For the fiscal year ending in December 2025, analysts expect SOLV's adjusted EPS to decline 11.9% year-over-year to $5.90. The company's earnings surprise history is mixed. It topped the consensus estimates in three of the last four quarters while missing on another occasion. Among the 13 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on four 'Strong Buy' ratings, eight 'Holds,' and one 'Strong Sell.' This configuration is more bullish than three months ago, with one 'Strong Buy' rating on the stock. On Aug. 8, Piper Sandler increased its price target on Solventum to $94 while maintaining an 'Overweight' rating. As of writing, the stock is trading below the mean price target of $87.12. The Street-high price target of $103 implies a modest potential upside of 44.2% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

U.S. pediatricians' new COVID-19 vaccine recommendations differ from CDC advice
U.S. pediatricians' new COVID-19 vaccine recommendations differ from CDC advice

Los Angeles Times

timean hour ago

  • Los Angeles Times

U.S. pediatricians' new COVID-19 vaccine recommendations differ from CDC advice

NEW YORK — For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine recommendations. The group's new COVID-19 recommendations — released Tuesday — come amid a tumultuous year for public health, as vaccine skeptics have come into power in the new Trump administration and government guidance has become increasingly confusing. This isn't going to help, acknowledged Dr. James Campbell, vice chair of the AAP infectious diseases committee. 'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. That differs from guidance established under U.S. Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. In a statement, Department of Health and Human Services spokesperson Andrew Nixon said 'the AAP is undermining national immunization policymaking with baseless political attacks.' He accused the group of putting commercial interests ahead of public health, noting that vaccine manufacturers have been donors to the AAP's Friends of Children Fund. The fund is currently paying for projects on a range of topics, including health equity and prevention of injuries and deaths from firearms. The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient. Stobbe writes for the Associated Press. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

FDA warns against eating possible radioactive shrimp sold at Walmart
FDA warns against eating possible radioactive shrimp sold at Walmart

UPI

timean hour ago

  • UPI

FDA warns against eating possible radioactive shrimp sold at Walmart

Aug. 19 (UPI) -- The U.S. Food and Drug Administration issued a public warning to not eat certain Great Value shrimp sold at Walmart because of it being possibly linked to contamination with the radioactive isotope Cesium-137. U.S. Customs and Border Protection detected possible Cesium-137, or Cs-137, in U.S.-bound shipments at four American ports of entry, the FDA said Tuesday in a release. However, U.S. heath officials added "at this time" no store product in U.S. markets has tested positive for Cesium-137 contamination. The health agency specifically alerted consumers about three Great Value brand frozen raw shrimps with a lot code: 8005540-1, and a best-by dates of March 15, 2027. In addition, there are other lot codes involved: 8005538-1 and 8005539-1. FDA officials said testing at the company distributor in Indonesia also tested positive. The FDA is working with distributors and retailers that may have received the tainted product from Indonesia-based PT. Bahari Makmur Sejati, which is doing business as BMS Foods. FDA officials said all products from the company are banned from U.S. entry "until the firm has resolved the conditions that gave rise to the appearance of the violation." "If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away," the FDA advised in its release. The FDA's investigation is ongoing.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store